Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

BACKGROUND: There is an unmet need to determine factors predictive of clinical benefit, to guide therapeutic sequencing and selection in metastatic RCC (mRCC). We evaluated clinical factors such as the neutrophil lymphocyte ratio (NLR) and duration of prior anti-vascular endothelial growth factor (V...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeyakumar, Ghayathri, Kim, Seongho, Bumma, Naresh, Landry, Craig, Silski, Cynthia, Suisham, Stacey, Dickow, Brenda, Heath, Elisabeth, Fontana, Joseph, Vaishampayan, Ulka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5646127/
https://www.ncbi.nlm.nih.gov/pubmed/29041991
http://dx.doi.org/10.1186/s40425-017-0287-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5646127/
https://www.ncbi.nlm.nih.gov/pubmed/29041991
http://dx.doi.org/10.1186/s40425-017-0287-5

Ejemplares similares